卵巢癌25例诊治临床分析

The clinical analysis of diagnosis and treatment about ovarian cancer 25 cases

目的:通过对卵巢癌患者临床病理特征进行总结,探讨卵巢癌诊治及防治策略。方法:收集近年在本院实施手术治疗的卵巢癌患者25例,对其临床症状、诊断、病理类型、治疗进行回顾分析。结果:患者平均年龄(53.64±11.6)岁,包块均径(106.01±49.54)mm。卵巢癌患者CA125、CA199、CEA和AFP均值分别为(711.15±1446.78)U/mL,(174.25±480.01)U/mL,(11.90±27.83)ng/mL,(5.01±9.59)ng/mL。CA125和CA199检出阳性率为80.0%和48.0%。采用FIGO标准进行全面分期手术,Ⅲ期以上实施肿瘤细胞减灭术。Ⅰ期患者17例、Ⅲ期患者7例、Ⅳ期患者1例。术后病理浆液性腺癌17例、粘液性腺癌4例、透明细胞癌1例、颗粒细胞瘤1例、生殖细胞肿瘤1例、转移性肿瘤1例,后续进一步静脉化疗和随访。结论:卵巢癌发病隐匿,病情进展迅速,手术和化疗是卵巢癌的主要治疗手段,采取可靠的筛查手段,可尽早发现卵巢癌,为手术创造时机,提高患者远期生存率和生存质量。随着卵巢癌突变基因筛选高危人群的临床普及,以及新的化疗药物临床推广,会为患者带来更多福音。

Objective:By summary the clinicopathologic characteristics of ovarian cancer,to explore diagnosis,treatment and prevention strategy.Methods:Collected 25 cases patients who suffered from ovarian cancer and executed operation treatment in our hospital,then carried out retrospective analysis about clinical symptoms,diagnosis,pathologic types and treatment.Results:The average age was(53.64±11.6),and the average diameter of mass was(106.01±49.54)mm.The mean value of tumor marker such as CA125,CA199,CEA,AFPwere(711.15±1446.78)U/mL,(174.25±480.01)U/mL,(11.90±27.83)ng/mL,(5.01±9.59)ng/mL,separately.The positive ratio of CA125 and CA199 were 80.0%and 48.0%.Applied FIGO standard to comprehensive staging surgery,executed cancer cytoreductive surgery at least three stage.Seventeen patients were in the first stage,phaseⅢpatients included seven cases,Ⅳstage had one patient.Postoperative pathology turned out to be serous adenocarcinoma with17 cases,mucinous adenocarcinoma about 4 cases,clear-cell carcinoma 1 case,granulosa cell tumor 1 case,germ cell tumor 1 case,metastatic tumor 1 case,further intravenous chemotherapy and follow-up survey.Conclusion:Ovarian cancer is a hidden onset and progress rapid disease.Surgery and chemotherapy are primary therapy measure.Applying reliable screening methods,in order to discover ovarian cancer as soon as possible,thus create opportunity to execute operation,as a result to improve survival and enhance life quality.Accompanied by clinical popularization screening of mutant genes in ovarian for high-risk population and clinical promotion new chemotherapeutic drugs,which will bring more gospel to patients.